atai Life Sciences (NASDAQ: ATAI), a trailblazer in the biopharmaceutical sector, focuses on revolutionizing mental health treatment. The company has announced its participation in the upcoming H.C. Wainwright 5th Annual Neuro Perspectives Conference on June 27, 2024. This event will feature atai’s management in a virtual fireside chat, complemented by individual investor meetings. Interested parties can access the chat on-demand beginning at 07:00 A.M. ET on the scheduled day, with a link provided for ease of access.
The conference chat and further insights into atai’s innovative approaches will remain accessible for 90 days in the Events section of atai’s investor website. atai Life Sciences, established to address the urgent needs unmet by existing mental health treatments, is committed to the development of new therapies for conditions such as depression, anxiety, addiction, and more. Their mission is underpinned by a commitment to fast-track the delivery of transformative treatments to foster sustained improvements in mental health outcomes.
For additional details about atai Life Sciences and their groundbreaking work in mental health, visit www.atai.life. For investor relations, contact IR@atai.life or for media inquiries, reach out to PR@atai.life.